ProKidney Corp.
NASDAQ:PROKBiotechnology
+$0.02 today
- Market cap
- $349.70M
- Beta
- 1.70
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$0.53
Volume 1.80M
Average 0.96M
PROK Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
ProKidney Corp.NASDAQ: PROK
Gross Profit · Q1 FY2026 · quarter ended Mar 2026
Gross profit turns negative
Q1 FY2026 gross profit was -$1.21M, compared with $230K a year earlier. Trailing-twelve-month gross profit was -$2M.
Context
- Gross profit amounted to 100.0% of revenue in FY2025, unchanged from a year earlier.
- Gross profit increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly gross profit holds near -$1.21M or moves back toward the trailing-twelve-month quarterly average of -$498.75K.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 893K USD
- Year-over-year change
- +1075.0%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 893K | +1075.0% |
| FY2024 | 2024-12-31 | 76K | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Gross Profit vs competitors
How PROK compares with its peers on the latest reported figures
- PROK's LTM Mar 2026 gross profit of -$2M is the lowest of the 7 companies compared; the peer median is $9.2M.
- Its year-over-year change of -752.0% is the lowest of 4, against a peer median of -7.2%.
- Gross profit amounts to 224.4% of revenue for PROK, versus a peer median of 91.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $394.98M | -7.2% | +66.0% | 60.7% | |
| LTM Mar 2026 | $393.18M | +29.0% | +96.5% | 91.9% | |
| LTM Mar 2026 | $18.41M | -89.0% | — | 92.0% | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Dec 2024 | -$120K | — | — | — | |
| LTM Mar 2026 | -$211K | — | — | — | |
| LTM Mar 2026 | -$2M | -752.0% | — | 224.4% | |
| Peer median (excluding PROK) | $9.2M | -7.2% | +81.3% | 91.9% | |
Competitors are the stored peer set for PROK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 76K | 893K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 76K | 893K |
| Gross Margin | — | — | — | 100.0% | 100.0% |
| Research & Development | 46.26M | 82.07M | 106.71M | 127.67M | 114.12M |
| Selling, General & Admin | 8.86M | 70.94M | 44.82M | 56.08M | 51.78M |
| Operating Expenses | 55.11M | 153.01M | 151.52M | 183.75M | 165.9M |
| Depreciation & Amortization | 1.98M | 3.04M | 3.85M | 5.43M | 6.58M |
| EBITDA | (53.12M) | (143.99M) | (125.59M) | (158.49M) | (144.62M) |
| EBITDA Margin | — | — | — | -208542.1% | -16194.7% |
| Operating Income | (55.11M) | (153.01M) | (151.52M) | (183.68M) | (165.01M) |
| Operating Margin | — | — | — | -241678.9% | -18477.8% |
| Interest Income | 2K | 5.98M | 22.08M | 19.75M | 13.81M |
| Interest Expense | 0 | 215K | 12K | 9K | 4K |
| Other Income / Expenses | 2K | 5.77M | 22.07M | 19.74M | 13.81M |
| Income Before Tax | (55.11M) | (147.24M) | (129.45M) | (163.93M) | (151.2M) |
| Pre-Tax Margin | — | — | — | -215701.3% | -16931.5% |
| Income Tax Expense | 38K | 896K | 6M | (598K) | 414K |
| Net Income | (55.15M) | (108.03M) | (35.47M) | (61.19M) | (68.99M) |
| Net Margin | — | — | — | -80507.9% | -7725.2% |
| EPS (Basic) | (1.73) | (1.76) | (0.57) | (0.62) | (0.52) |
| EPS (Diluted) | (1.73) | (1.76) | (0.57) | (0.62) | (0.52) |
| Weighted Avg Shares | 31.89M | 61.54M | 61.71M | 97.92M | 133.94M |
| Weighted Avg Shares (Diluted) | 31.89M | 61.54M | 61.71M | 97.92M | 133.94M |
ProKidney Corp.
NASDAQ:PROK
Intrinsic Alpha fair value
Locked
Current Price
$1.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.